ライフサイエンスコーパス: alpha 2-macroglobulin

1 tissue inhibitor of metalloproteinases-1 and alpha 2-macroglobulin.

2 cluding vitronectin, C-reactive protein, and alpha-2-macroglobulin.

3 transferrin, alpha-lactalbumin, insulin, and alpha-2-macroglobulin.

4 immunoprecipitated C4 complement protein and alpha-2-macroglobulin.

5 uch as TIMPs and/or the acute phase reactant alpha-2-macroglobulin.

6 tein in the presence or absence of activated alpha(2)-macroglobulin.

7 (IL-6)-induced acute-phase response protein, alpha(2)-macroglobulin.

8 wn to be greatly enhanced in the presence of alpha(2)-macroglobulin.

9 mplete" serum that contains C1-inhibitor and alpha(2)-macroglobulin.

10 on with the receptor binding domain of human alpha(2)-macroglobulin.

11 se inhibitor, alpha(1)-antichymotrypsin, and alpha(2)-macroglobulin.

12 bitors such as tissue inhibitors of MMPs and alpha(2)-macroglobulins.

13 The ability of cells to bind alpha(2) macroglobulin, a previously known CD91 ligand,

14 The protease inhibitor alpha(2)-macroglobulin (A2M) is a member of the ancient

15 st examined whether the acute-phase protein, alpha-2 macroglobulin (A2M), a major component of the in

16 reaction, nephelometry, and Western blot for alpha-2-macroglobulin (A2M) and activated partial thromb

17 nse mutation in the evolutionarily conserved alpha-2-macroglobulin (A2M) domain of CPAMD8, c.4351T>C

18 e ratio (S/N) for immunoglobulin G (IgG) and alpha-2-macroglobulin (A2M) ions, with increases of 68.0

19 Alpha-2-Macroglobulin (A2M) is a highly plausible candid

20 Alpha-2-Macroglobulin (A2M) is the critical pan-protease

21 ve protein (CRP), serum amyloid P (SAP), and alpha-2-macroglobulin (A2M).

22 Eight genes (alpha-2-macroglobulin [A2M], creatine kinase [CKB], angi

23 ly captures protease catalysts by repurposed alpha-2-macroglobulin (A2Ms).

24 rized into serpins, canonical inhibitors and alpha-2-macroglobulins (A2Ms).

25 se-9, tissue-type plasminogen activator, and alpha(2)-macroglobulin activated Rac1 in LRP1-expressing

26 a with a mixture of pure C1-inhibitor and/or alpha(2)-macroglobulin added together with MBL-MASP, all

27 alpha1-proteinase inhibitor (alpha 1-PI) and alpha 2-macroglobulin (alpha 2-M) are reduced, especiall

28 y of activated factor X (factor Xa) binds to alpha 2-macroglobulin (alpha 2M) and is rapidly cleared

29 We have characterized four human alpha 2-macroglobulin (alpha 2M) bait region variants (G

30 alpha 2-Macroglobulin (alpha 2M) is a complex tetrameric

31 alpha 2-Macroglobulin (alpha 2M) is a high-affinity, bro

32 alpha 2-Macroglobulin (alpha 2m) is a major plasma prote

33 Receptor-recognized forms of alpha 2-macroglobulin (alpha 2M*) bind to two macrophage

34 alpha(2) macroglobulin (alpha(2)M) or serum is sufficien

35 Alpha(2)-macroglobulin (alpha(2)M) and its receptor, low

36 In the present studies we identify alpha(2)-macroglobulin (alpha(2)M) as an additional endo

37 alpha(2)-Macroglobulin (alpha(2)M) binds transforming gr

38 tron microscopy reconstructions of the human alpha(2)-macroglobulin (alpha(2)M) dimer and chymotrypsi

39 alpha(2)-Macroglobulin (alpha(2)M) functions as a protei

40 alpha(2)-Macroglobulin (alpha(2)M) is a highly conserved

41 alpha(2)-Macroglobulin (alpha(2)M) is a plasma protease

42 The human plasma proteinase inhibitor alpha(2)-macroglobulin (alpha(2)M) regulates cellular gr

43 receptor-associated protein and by activated alpha(2)-macroglobulin (alpha(2)M), suggesting the parti

44 In the current study, we employed alpha(2)-macroglobulin (alpha(2)M)-agarose column chroma

45 t LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M).

46 1 was identified initially as a receptor for alpha(2)-macroglobulin (alpha(2)M).

47 lysis identified this co-purified protein as alpha(2)-macroglobulin (alpha(2)M).

48 (TGF-beta(1,2)) are known to be modulated by alpha(2)-macroglobulin (alpha(2)M).

49 pe plasminogen activator (EI-tPA); activated alpha(2)-macroglobulin (alpha(2)M); and S-PrP, a soluble

50 We found that activated alpha(2)-Macroglobulin (alpha(2)M*) a ligand of the CS-G

51 in receptors by receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) activates various si

52 tivated form of the pan-proteinase inhibitor alpha(2)-macroglobulin (alpha(2)M*) and amyloid precurso

53 Receptor-recognized forms of alpha(2)-Macroglobulin (alpha(2)M*) bind to LRP, but the

54 complexed to the receptor-recognized form of alpha(2)-macroglobulin (alpha(2)M*) demonstrate enhanced

55 ages exposed to receptor-recognized forms of alpha(2)-macroglobulin (alpha(2)M*) demonstrate increase

56 as a receptor binding to the active form of alpha(2)-macroglobulin (alpha(2)M*), activating thus sev

57 We report that the LRP ligand, activated alpha(2)-macroglobulin (alpha(2)M*), induces robust calc

58 rface GRP78 by its natural ligand, activated alpha(2)-macroglobulin (alpha(2)M*), results in a 2-3-fo

59 gnized by its physiologic agonist, activated alpha(2)-macroglobulin (alpha(2)M*).

60 4 and the receptors for transferrin (Tf) and alpha(2)-macroglobulin (alpha-2-M; LRP-1) were compared

61 ent than that of the closely related protein alpha-2-macroglobulin (alpha(2)M), although the chaperon

62 ding complement factor H (CFH) precursor and alpha-2-macroglobulin (alpha-2M).

63 Alpha-2-macroglobulin (alpha-2M; encoded by the gene A2M

64 G antibody [EndoCAb]), acute-phase proteins (alpha-2 macroglobulin [alpha-2M], C-reactive protein [CR

65 system, we examined the effects of activated alpha(2)-macroglobulin (alpha2M*), a ligand of LRP, on i

66 From this screen, we identified alpha-2-macroglobulin (alpha2M).

67 (AGP), haptoglobin phenotype 1-1 (Hp1-1) and alpha-2-macroglobulin (alpha2M).

68 e and correlate salivary and serum PAI-1 and alpha 2-macroglobulin (alpha2MG) in patients with period

69 ayer-by-layer (LbL) microcapsules to deliver alpha-2-macroglobulin (alpha2MG), a protein with modulat

70 nt role in the clearance of plasma-activated alpha 2-macroglobulin and apolipoprotein E-enriched lipo

71 d protein (LRP), a cell surface receptor for alpha 2-macroglobulin and other ligands.

72 ence-specific manner to the promoters of the alpha(2)-macroglobulin and Aalpha-fibrinogen genes and t

73 istry revealed foci of albumin, transferrin, alpha(2)-macroglobulin and IgG transudation around blood

74 rotein toxicity in the presence of activated alpha(2)-macroglobulin and its down-regulation via inhib

75 Ad7 partially colocalized with alpha(2)-macroglobulin and late endosomal and lysosomal

76 nds receptor-associated protein or activated alpha(2)-macroglobulin and occurred primarily via a flui

77 12 that contains the genes that encode both alpha(2)-macroglobulin and the low-density lipoprotein r

78 the LRP1/NMDA-R system, including activated alpha(2)-macroglobulin and tissue-type plasminogen activ

79 ly that includes the pan-protease inhibitors alpha(2)-macroglobulins and vertebrate complement factor

80 ivator (tPA), apolipoprotein E/lipoproteins, alpha(2)-macroglobulin, and the beta-amyloid precursor p

81 revealed a receptor for the peptide PKRGFQD, alpha-2-macroglobulin, and for SNTRVAP, 78-kDa glucose-r

82 These results indicate that GRP78 and alpha-2-macroglobulin are highly active in osteoblastic,

83 BMP1 is shown to cleave the alpha(2)-macroglobulin "bait" region, at a single specif

84 Whereas a clear role for CD91 in alpha(2)-macroglobulin binding and uptake was readily ob

85 roximately 7-fold) and the protein G-related alpha(2)-macroglobulin-binding protein (grab; approximat

86 alpha(2)-Macroglobulin-bound chymase generates angiotens

87 The present work shows that alpha(2)-macroglobulin-bound chymase remains accessible

88 proteinase as shown by its ability to cleave alpha(2)-macroglobulin, but it does not cleave specific

89 acterized a novel member of the complement 3/alpha(2)-macroglobulin (C3/alpha(2)M) family named CPAMD

90 angiotensin II-generating activity, and that alpha(2)-macroglobulin capture may be exploited in asses

91 We used alpha(2)-macroglobulin capture to develop a sensitive, m

92 glycoprotein 1, alpha-1-acid glycoprotein 1, alpha-2-macroglobulin, complement C3, mannose-binding pr

93 ntified mutations in CPAMD8 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8) as th

94 nterferon gene response (GAS) element in the alpha(2)-macroglobulin enhancer, Stat1 did not stimulate

95 transient-transfection experiments with the alpha(2)-macroglobulin enhancer, Stat3 and c-Jun coopera

96 e in driving transcription controlled by the alpha(2)-macroglobulin enhancer.

97 n IL-6-induced transcription directed by the alpha(2)-macroglobulin enhancer.

98 The levels of five acute-phase proteins (alpha-2 macroglobulin, haptoglobin, serum amyloid P, pro

99 g ectopic expression of modified versions of alpha(2)-macroglobulin in the treatment of fibrotic cond

100 also demonstrated that genetically modified alpha(2)-macroglobulin, in which the native bait region

101 partially competitively inhibited by excess alpha(2)-macroglobulin, indicating that hspRs in additio

102 The previously known CD91 ligand, alpha 2-macroglobulin, inhibits re-presentation of gp96-

103 n idiopathic dilated cardiomyopathy, whereas alpha 2-macroglobulin is high.

104 These findings suggest that chymase bound to alpha(2)-macroglobulin is active, that the complex is an

105 alpha(2)-Macroglobulin is an irreversible inhibitor that

106 Expression of the acute phase protein alpha(2)-macroglobulin is induced in vivo by interleukin

107 viously been reported that the serum protein alpha(2)-macroglobulin is unable to inhibit the astacin-

108 ells adhered to immobilized fetuin-A and not alpha(2)-macroglobulin, its major contaminant.

109 Human alpha(2)-macroglobulin-like protein 1 (A2ML1) is a monom

110 nactivated alpha(1)-proteinase inhibitor and alpha(2)-macroglobulin lose the spreading activity, indi

111 proteins, alpha 1-antichymotrypsin (ACT) and alpha 2-macroglobulin (MAC), and cognitive impairment in

112 blood cells but precipitated only with human alpha(2)-macroglobulin, of many glycoproteins and polysa

113 RP1 agonists (the receptor binding domain of alpha-2-macroglobulin or the hemopexin domain of matrix

114 In contrast, the lowest quintiles of alpha-2-macroglobulin (OR = 3.71, CI = 1.21-11.33), ferr

115 he addition of excess CD91 ligand, activated alpha(2)-macroglobulin, or receptor-associated protein,

116 air synergy between STAT3-C and c-Jun at the alpha(2)-macroglobulin promoter in HepG2 cells, suggesti

117 DNA elements contribute to activation of the alpha(2)-macroglobulin promoter in response to IL-6 fami

118 Human alpha(2)-macroglobulin-proteinase complexes bind to thei

119 The CD91 molecule (also called alpha 2-macroglobulin receptor or the low density lipopr

120 hen scuPA bound to suPAR, a binding site for alpha 2-macroglobulin receptor/LDL receptor-related prot

121 PE) binds and enters mammalian cells via the alpha 2-macroglobulin receptor/low density lipoprotein r

122 scuPA to vitronectin, thombospondin, and the alpha 2-macroglobulin receptor/low-density lipoprotein-r

123 density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP) antibodies.

124 density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor.

125 rect association with the endocytic receptor alpha(2)-macroglobulin receptor/low density lipoprotein

126 The alpha(2-)macroglobulin receptor (alpha(2)MR) has been re

127 ts were obtained for another ligand of LDLR, alpha-2-macroglobulin receptor-associated protein (RAP),

128 tic receptor protein CD91, also known as the alpha-2-macroglobulin receptor.

129 Ligation of alpha(2)-macroglobulin receptors by receptor-recognized

130 , sLRP2 bound the receptor-binding domain of alpha(2)-macroglobulin (residues 1304-1451).

131 A molecule related to the protease inhibitor alpha-2-macroglobulin responded strongly to malaria para

132 d insulin-dependent regulation of macrophage alpha(2)-macroglobulin signaling receptors (alpha(2)MSR)

133 croglobulin (A2M) is a member of the ancient alpha(2)-macroglobulin superfamily (A2MF), which also in

134 Significant increases in serum levels of alpha-2-macroglobulin that correspond to changes in its

135 Three ligands were chemorepulsive: alpha-2-macroglobulin, tissue plasminogen activator, and

136 alpha and meprin beta, we herein demonstrate alpha(2)-macroglobulin to be a potent inhibitor of the s

137 k(off)) for MMP-1 and MMP-3 determined using alpha(2)-macroglobulin to capture MMP dissociating from

138 ir ability to process peptides chaperoned by alpha(2) macroglobulin, undergo identical variations.

139 ession of transforming growth factor beta 1, alpha 2 macroglobulin, vascular endothelial growth facto

140 changed activity in PC-12 cells, even though alpha(2)-macroglobulin was reduced to undetectable level

141 OET-11, an alpha(2) macroglobulin, was expressed by the receptor ne

142 ved that systemic inflammation, indicated by alpha-2-macroglobulin, was elevated in the initial stage

143 For another gene, encoding a putative alpha-2-macroglobulin, we found evidence of positive sel

144 0, TNF-alpha, CRP, sVCAM1, sICAM1, suPAR and alpha-2-macroglobulin were measured using immunoassays.

145 sence of multiple plasma proteins, including alpha(2)-macroglobulin, which is reported to regulate PC

146 ng antipeptidases, but is mostly captured by alpha(2)-macroglobulin, which sequesters peptidases in a